Medtech companies Mologic and BioSure have joined forces on a coronavirus antibody self-test that is designed to be used quickly and easily and return results within ten minutes from just a fraction of a drop of blood.

The test uses Mologic’s COVID-19 lateral flow test, combined with a BioSure-designed kit. The kit is expected to be ready for mass production from early June, available in the UK, global markets and for direct purchase.

Mologic CEO Mark Davis commented: “Mologic is thrilled to be partnering with BioSure on this COVID-19 self-test, which will enable people to quickly and safely test for antibodies to the virus in their own home.”

“The team and our independent validation partners have worked tirelessly to develop and optimise this quality rapid diagnostic in record time and this partnership brings it one step closer getting it on the market. To all those that have contributed to this project and supported us thus far, I offer my sincere gratitude.”

BioSure CEO Brigette Bard, meanwhile, said: “We are incredibly proud to announce our partnership with Mologic, the world-leading scientific researchers. Our companies are very aligned in their dynamic thinking and the way we both have a strong passion to find solutions to problems.”

“Their expertise and creativity mean that together we have an outstanding test, that everyone, everywhere, will be able to test on their own terms.”

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX